JP6000259B2 - 止血障害治療用第ｉｉ因子およびフィブリノーゲン - Google Patents

止血障害治療用第ｉｉ因子およびフィブリノーゲン Download PDF

Info

Publication number
JP6000259B2
JP6000259B2 JP2013532104A JP2013532104A JP6000259B2 JP 6000259 B2 JP6000259 B2 JP 6000259B2 JP 2013532104 A JP2013532104 A JP 2013532104A JP 2013532104 A JP2013532104 A JP 2013532104A JP 6000259 B2 JP6000259 B2 JP 6000259B2
Authority
JP
Japan
Prior art keywords
fibrinogen
fii
blood
combination
clotting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013532104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538863A5 (cg-RX-API-DMAC10.html
JP2013538863A (ja
Inventor
アン・ロヴグレン
ケニー・ハンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6000259(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2013538863A publication Critical patent/JP2013538863A/ja
Publication of JP2013538863A5 publication Critical patent/JP2013538863A5/ja
Application granted granted Critical
Publication of JP6000259B2 publication Critical patent/JP6000259B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2013532104A 2010-10-06 2011-09-19 止血障害治療用第ｉｉ因子およびフィブリノーゲン Expired - Fee Related JP6000259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
US61/390,224 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (3)

Publication Number Publication Date
JP2013538863A JP2013538863A (ja) 2013-10-17
JP2013538863A5 JP2013538863A5 (cg-RX-API-DMAC10.html) 2014-11-20
JP6000259B2 true JP6000259B2 (ja) 2016-09-28

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532104A Expired - Fee Related JP6000259B2 (ja) 2010-10-06 2011-09-19 止血障害治療用第ｉｉ因子およびフィブリノーゲン

Country Status (16)

Country Link
US (1) US9433664B2 (cg-RX-API-DMAC10.html)
EP (1) EP2624859B1 (cg-RX-API-DMAC10.html)
JP (1) JP6000259B2 (cg-RX-API-DMAC10.html)
KR (1) KR20130136988A (cg-RX-API-DMAC10.html)
CN (1) CN103221061A (cg-RX-API-DMAC10.html)
AU (1) AU2011313505B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013008034A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812888A1 (cg-RX-API-DMAC10.html)
DK (1) DK2624859T3 (cg-RX-API-DMAC10.html)
ES (1) ES2625153T3 (cg-RX-API-DMAC10.html)
HU (1) HUE033204T2 (cg-RX-API-DMAC10.html)
MX (1) MX343784B (cg-RX-API-DMAC10.html)
PL (1) PL2624859T3 (cg-RX-API-DMAC10.html)
RU (1) RU2606155C2 (cg-RX-API-DMAC10.html)
SG (2) SG188639A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012045569A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
SG10201912497WA (en) * 2017-02-09 2020-02-27 Csl Behring Gmbh A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3165600D1 (en) * 1980-01-28 1984-09-27 Baxter Travenol Lab Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
SI0796623T1 (en) * 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
CA2437015A1 (en) 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
IL159622A0 (en) * 2001-07-20 2004-06-01 Novo Nordisk Healthcare Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
EP1587424A4 (en) 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP2165711B1 (en) 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
RU2008139428A (ru) * 2006-03-06 2010-05-20 Хьюмэджин, Инк. (Us) Способ получения рекомбинантного тромбина и фибриногена человека
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
US20090148502A1 (en) 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
EP2131776A1 (en) 2007-03-30 2009-12-16 Thrombodyne Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
CA2740079A1 (en) 2008-10-08 2010-04-15 Thrombodyne, Inc. Methods of making concentrated fibrinogen- and platelet-containing compositions
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY

Also Published As

Publication number Publication date
SG10201508159SA (en) 2015-10-29
WO2012045569A1 (en) 2012-04-12
BR112013008034A2 (pt) 2016-06-14
EP2624859A1 (en) 2013-08-14
ES2625153T3 (es) 2017-07-18
US9433664B2 (en) 2016-09-06
KR20130136988A (ko) 2013-12-13
CN103221061A (zh) 2013-07-24
MX2013003715A (es) 2013-09-26
JP2013538863A (ja) 2013-10-17
SG188639A1 (en) 2013-05-31
US20130280236A1 (en) 2013-10-24
AU2011313505B2 (en) 2015-09-17
AU2011313505A1 (en) 2013-04-11
RU2606155C2 (ru) 2017-01-10
RU2013120033A (ru) 2014-11-20
WO2012045569A9 (en) 2016-01-07
HUE033204T2 (en) 2017-11-28
MX343784B (es) 2016-11-23
EP2624859B1 (en) 2017-03-01
PL2624859T3 (pl) 2017-09-29
CA2812888A1 (en) 2012-04-12
DK2624859T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
JP2013538863A (ja) 止血障害治療用第ｉｉ因子およびフィブリノーゲン
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
Sharma et al. Tranexamic acid leads to paradoxical coagulation changes during cardiac surgery: a pilot rotational thromboelastometry study
JP2004527554A (ja) Ａｒｄｓの処理における修飾されたｆｖｉｉ
Downey et al. Coagulation, cardiopulmonary bypass, and bleeding
HK1188391A (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
HK1188391B (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
KR20120022717A (ko) 피브리노겐의 신규 용도
Tang et al. Factor XIII deficiency does not prevent FeCl
Van Poucke et al. THROMBIN GENERATION AND PLATELET ACTIVATION IN CRS/HIPEC.
Braunschweig et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig...

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160830

R150 Certificate of patent or registration of utility model

Ref document number: 6000259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees